RecruitingPhase 1NCT06324396
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
Studying Fontan-associated liver disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Mercy Hospital Kansas City
- Principal Investigator
- Jonathan Wagner, DOChildren's Mercy
- Intervention
- Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Children's Mercy Hospital, Kansas City, Missouri, United States
Collaborators
Indiana Clinical and Translational Sciences Institute · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06324396 on ClinicalTrials.govOther trials for Fontan-associated liver disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07009132Cholate Clearance in Fontan and Heart FailureHepQuant, LLC
- RECRUITINGNCT05213598Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity AssessmentNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- ACTIVE NOT RECRUITINGNCT03914196Fontan Associated Liver DiseaseChildren's Hospital Medical Center, Cincinnati